Oric Pharmaceuticals
ORIC
182 hedge funds and large institutions have $1.51B invested in Oric Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 57 increasing their positions, 63 reducing their positions, and 22 closing their positions.
86% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 22
54% more capital invested
Capital invested by funds: $980M → $1.51B (+$530M)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
11% more funds holding
Funds holding: 164 → 182 (+18)
8% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $959K
10% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 63
3.93% less ownership
Funds ownership: 122.86% → 118.93% (-3.9%)
Top Buyers
| 1 |
ACM
AIHC Capital Management
Central,
|
+$27.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$23.8M |
| 3 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$22.6M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$12.8M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$11.4M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$23.9M |
| 2 |
VA
VR Adviser
New York
|
-$15.4M |
| 3 |
O
OrbiMed
New York
|
-$10.8M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
-$8.49M |
| 5 |
Barclays
London,
United Kingdom
|
-$8.02M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$18K | -2,344 | Closed |
|
|
AB
202
Amalgamated Bank
New York
| – | -$17K | -2,078 | Closed |
|
|
II
203
Inspire Investing
Meridian,
Idaho
| – | -$6.16K | -753 | Closed |
|
204
Daiwa Securities Group
Tokyo,
Japan
| – | -$2K | -249 | Closed |
|
ORIC Hedge Fund Activity: Q1 2026 in Review
182 of the 8,125 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q1 2026, worth a combined $1.51B — up 54% from $980M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new ORIC positions and 22 closed out — a net gain of 19 holders — while 57 added to existing stakes and 63 trimmed.
The largest buyer was AIHC Capital Management, opening a new position worth an estimated $27.9M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $23.9M sold.
- 182 institutional investors held Oric Pharmaceuticals (ORIC) as of Q1 2026, up from 164 in Q4 2025.
- Funds reported $1.51B of Oric Pharmaceuticals stock for Q1 2026, up 54% quarter-over-quarter.
- 41 funds opened new Oric Pharmaceuticals positions in Q1 2026 and 22 closed out, a net change of +19 holders.
- The largest Oric Pharmaceuticals buyer in Q1 2026 was AIHC Capital Management, an estimated $27.9M added.
- The largest Oric Pharmaceuticals seller in Q1 2026 was Point72 Asset Management, an estimated $23.9M sold.
Based on aggregated 13F filings for Q1 2026.